Cantor Fitzgerald initiates Verastem (VSTM) at Buy with a $22 price target noting the company's "scientific and executive founders are a virtual panoply of who's who in cancer stem cell research." Furthermore, analyst Mara Goldstein says the company has a "compelling mix" of other catalysts and VS-6063 (previous) may have applications outside of mesothelioma.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs